Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  AVEO Pharmaceuticals, Inc.    AVEO

News SummaryMost relevantAll newsSector newsTweets

AVEO Pharmaceuticals, Inc. : DEADLINE ALERT: Rigrodsky & Long, P.A. Reminds Shareholders of AVEO Pharmaceuticals, Inc. of Upcoming Deadline

share with twitter share with LinkedIn share with facebook
share via e-mail
06/25/2013 | 11:25pm CEST

Rigrodsky & Long, P.A.:

  • Do you, or did you, own shares of AVEO Pharmaceuticals, Inc. (NASDAQ GS: AVEO)?
  • Did you purchase your shares before January 3, 2012, or between January 3, 2012 and May 1, 2013, inclusive?
  • Did you lose money in your investment in AVEO Pharmaceuticals, Inc.?
  • Do you want to discuss your rights?

Rigrodsky & Long, P.A., including former Special Assistant United States Attorney, Timothy J. MacFall, reminds shareholders of AVEO Pharmaceuticals, Inc. ("AVEO" or the "Company") (NASDAQ GS: AVEO) of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company.

A complaint was filed in the United States District Court for the District of Massachusetts on behalf of all persons or entities that purchased the common stock of AVEO between January 3, 2012 and May 1, 2013, inclusive (the "Class Period"), alleging violations of the Securities Exchange Act of 1934 against the Company and certain of its officers (the "Complaint"). If you wish to serve as lead plaintiff, you must move the Court no later than July 8, 2013.

If you purchased shares of AVEO during the Class Period, or purchased shares prior to the Class Period and still hold AVEO, and wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact Timothy J. MacFall, Esquire or Peter Allocco of Rigrodsky & Long, P.A., 825 East Gate Boulevard, Suite 300, Garden City, NY at (888) 969-4242, by e-mail to [email protected], or at: http://www.rigrodskylong.com/investigations/aveo-pharmaceuticals-inc-aveo.

A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. In order to be appointed lead plaintiff, the Court must determine that the class member's claim is typical of the claims of other class members, and that the class member will adequately represent the class. Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff. Any member of the proposed class may move the court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.

While Rigrodsky & Long, P.A. did not file the Complaint in this matter, the firm, with offices in Wilmington, Delaware and Garden City, New York, regularly litigates securities class, derivative and direct actions, shareholder rights litigation and corporate governance litigation, including claims for breach of fiduciary duty and proxy violations in the Delaware Court of Chancery and in state and federal courts throughout the United States.

Attorney advertising. Prior results do not guarantee a similar outcome.

Rigrodsky & Long, P.A.
Timothy J. MacFall, Esquire
Peter Allocco
Fax: 302-654-7530
[email protected]

© Business Wire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
09/20 AVEO PHARMACEUTICALS : Flat on New Study with EUSA
09/20 AVEO ONCOLOGY : and EUSA Pharma Announce TiNivo Combination Study Opt-in
09/13 AVEO ONCOLOGY : Announces Receipt of Payments from EUSA Pharma and CANbridge
09/08 AVEO PHARMACEUTICALS, INC. : Today's Research Reports on Trending Tickers: AVEO ..
09/05 AVEO ONCOLOGY : to Present at Upcoming Conferences
08/30 AVEO PHARMACEUTICALS, INC. : Featured Company News - AVEO Pharma's FOTIVDA(R) Li..
08/28 AVEO PHARMACEUTICALS : Shares Flat Following EC Approval
08/28 AVEO ONCOLOGY : Announces FOTIVDA® (tivozanib) Approved in the European Union fo..
08/17 AVEO PHARMACEUTICALS, INC. (NASDAQ : AVEO) Files An 8-K Departure of Directors o..
08/17 AVEO PHARMACEUTICALS INC : Change in Directors or Principal Officers (form 8-K)
More news
News from SeekingAlpha
09/20 AVEO to receive $2M payment after EUSA elects to enter TiNivo study
09/14 ROTY VOLUME 1 EDITION 30 : Nuggets From Recent Presentations And Updates
09/13 AVEO Pharmaceuticals (AVEO) Presents At Rodman & Renshaw 19th Annual Global I..
09/07 TAKEOVER RUMOR DU JOUR : AVEO Pharma by Jazz Pharma
09/05 ROTY VOLUME 1 EDITION 27 : Spring Bank And Anaptysbio Making Moves Higher + A Ne..
Financials ($)
Sales 2017 9,61 M
EBIT 2017 -31,1 M
Net income 2017 -57,8 M
Debt 2017 -
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales 2017 44,3x
Capi. / Sales 2018 35,0x
Capitalization 426 M
Duration : Period :
AVEO Pharmaceuticals, Inc. Technical Analysis Chart | AVEO | US0535881090 | 4-Traders
Technical analysis trends AVEO PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 1
Average target price 4,50 $
Spread / Average Target 25%
EPS Revisions
Michael P. Bailey President, Chief Executive Officer & Director
Matthew D. Dallas Chief Financial Officer
Michael N. Needle Chief Medical Officer
Emile Farhan Vice President-Technical Operations
Anthony B. Evnin Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
AMGEN28.70%136 186
GILEAD SCIENCES15.40%107 896